Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

20 Apr 2020

1110.00

-0.66%

Aurobindo Pharma Limited

Hold: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

On the business front, despite the nationwide lockdown, domestic growth is expected to remain more or less stable. Exports growth, barring for one or two months due to congestion in all major ports globally, is also expected to remain strong due to 1) currency benefit, 2) slowdown in competition due to delay in new approvals that will be beneficial for existing players and 3) expected demand continuum across the world despite Covid-19. Some windfall is also expected in some critical productsa case in point is Hydroxychloroquine, a malaria drug that is likely to be repurposed as a prophylaxis for Covid-19 treatment in some cases....

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.6

Aurobindo Pharma Ltd.

03 Apr 2020

1110.00

-0.66%

Event Update - Sandoz deal mutually called off - Under Review

Sell: Aurobindo Pharma Ltd.

Recommendation

Prabhudas Lilladhar

ARBP has mutually terminated its proposed acquisition of Sandoz asset (Novartis generic subsidiary). ARBP planned to acquire a part of Sandoz's generic business including oral solid and dermatology products in CY18 while expecting to wind up the deal by CY-20 March with USFTC's approval. With US$1,200m sales, ARBP agreed for the deal value of $US900mn and an additional payment of US$100m based on revenue milestones with the entire amount was to be funded by debt. While our estimated earning has not discounted potentials from Sandoz deal, we placed ARBP UNDER REVIEW'...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

03 Apr 2020

1110.00

-0.66%

Aurobindo Pharma Limited

Hold: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

Background- Aurobindo's US subsidiary had entered into an agreement in September, 2018 to acquire Sandoz's dermatology and oral solid businesses in the US for a cash consideration of US$900 million. The acquired business was supposed to comprise 1) portfolio of dermatology, oral solids, 2) authorised generics, in-licensed products, branded dermatology products, 3) three manufacturing facilities at Hicksville - NY (Derma), Melville NY (Derma), Wilson - NC (OSD) besides entire holding in Eon Labs Inc, a wholly owned subsidiary of Sandoz. Net sales of the proposed acquired business...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.6

Aurobindo Pharma Ltd.

02 Apr 2020

1110.00

-0.66%

Aurobindo Pharma (BUY): Sandoz deal called off; upgrade to BUY

Buy: Aurobindo Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Aurobindo Pharma (ARBP) announced that the deal to buy Sandoz's US generic oral solids and dermatology business has been mutually called off.

Aurobindo Pharma Ltd. has lost -25.82% in the last 1 Year

Aurobindo Pharma Ltd.

16 Mar 2020

1110.00

-0.66%

Health Check - Monthly Update

Mgmt Note: Aurobindo Pharma Ltd.

ICICI Securities Limited

In another adverse USFDA update, Cipla's Goa manufacturing facility received a warning letter (WL) from USFDA for the inspection conducted in September 16-27, 2019 post which the unit had received 12 observations. However, this warning letter was already expected post the assignment of official action indicated (OAI) status in January 2020. On the Indian pharma market front, the DGFT has restricted export of 13...

Aurobindo Pharma Ltd. is trading above its 50 day SMA of 1087.6

Aurobindo Pharma Ltd.

11 Mar 2020

1110.00

-0.66%

Observations at Unit 12 resolvable on robust CAPA

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

11 March 2020 The USFDA inspected ARBPs Unit 12 as part of cGMP compliance and issued form environment, equipment and product by personnel or environmental condition, which could potentially affect product quality. Specific remarks were made on flow of materials, qualification of clean rooms and procedure to control operator access to clean rooms. (2) Procedures to prevent microbial contamination not established. (5) Issues with handling of complaints. (6) Non-establishment of sensitivity of test methods. We expect these issues to be resolved within 3-6 months post robust CAPA. Note that this site was last inspected in Mar18 and classified as VAI. ARBP manufactures penicillin (orals and injectables) at Unit 12. All 20 ANDAs filed from this site are already approved (no pending approvals). Unit 12 accounts for 3-4% of US sales as a single-source facility. Over the past one year, nine sites have been inspected by the USFDA.

Aurobindo Pharma Ltd. is trading below its 100 day SMA of 1124.9

Aurobindo Pharma Ltd.

09 Mar 2020

1110.00

-0.66%

Sector Update - Re-emergence of regulatory threat to undermine earnings in near-term

Sell: Aurobindo Pharma Ltd.

Prabhudas Lilladhar

FDA continues to maintain zero tolerance towards injectable units Indian generics ranked 2nd only after US for non-compliance issues of facilities by FDA. With the regulators focus towards approving more generics, Indian majors were short of compliance that led to missed opportunity of launching day-one generics and specialty products in CY19. With USFDA issued WL in CY19 to the Indian majors, the track record of achieving compliance in injectable plant were in shambles as work culture in sterile plant lacked training and integrity. The resolution might take longer than its...

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

24 Feb 2020

1110.00

-0.66%

Aurobindo Pharma Limited

Hold: Aurobindo Pharma Ltd.

ICICI Securities Limited

Rescindment of the VAI status for Unit IV just three days after it was issued (February 18, 2020) is indeed a unique case with negative sentimental implications. Unit IV is a critical plant for the company, given most of its pending injectables are filed from this plant. Injectable segment is one of the key drivers for the company's future growth and margins. OAI status for Unit VII just two weeks back and now the rescinded VAI status for Unit IV from USFDA does not bode well for the company. The lingering cGMP issues and, in particular, issues including some important plants like Unit IV and Unit VII...

Aurobindo Pharma Ltd. has an average target of 1403.50 from 10 brokers.

Aurobindo Pharma Ltd.

22 Feb 2020, 12:00AM

1110.00

-0.66%

Aurobindo Pharma (ADD): USFDA error on Unit IV to erase recent stock gains

Sell: Aurobindo Pharma Ltd.

Recommendation Target

BOB Capital Markets Ltd.

Aurobindo Pharma (ARBP) has received further communication from the USFDA on its Unit IV injectable plant stating that the inspection is still open and under review.